ORCHID PHARMA
|
|
BOM : 524372     NSE : ORCHPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Sep 10,2024 |
Price(EOD): ₹ 1,508.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 7,649.36 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ORCHID PHARMA | 4.1% | 5% | 169.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.6% | 4.9% | 64.5% |
CIPLA | -2% | 3.3% | 30.1% |
DR REDDYS LABORATORIES | -2.9% | -4.1% | 17.8% |
ZYDUS LIFESCIENCES | -0.8% | -13.7% | 77.3% |
DIVIS LABORATORIES | 2.1% | 7% | 41.5% |
FUNDAMENTAL ANALYSIS OF ORCHID PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ORCHID PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
68.33
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 111.99 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 6.54
P/B Calculated based on Book Value of Rs 1,169.47 Cr
[Latest Year - Mar2024 - Consolidated Results ] 8.69
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 880.85 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
61% 107% 545% |
SHARE PRICE MOMENTUM OF ORCHID PHARMA
ORCHID PHARMA vs SENSEX
DEBT OF ORCHID PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.11 0.45 0.4 0.32 |
0.12 0.48 0.41 0.34 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ORCHID PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ORCHID PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
12.58% 12.36% -7.44% -15.6% |
33.61% 46.74% 160.98% 162.41% |
QtrlyTrend |
4 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
ORCHID PHARMA related INDICES
You may also like the below Video Courses
FAQ about ORCHID PHARMA
Is ORCHID PHARMA good for long term investment?
As on Sep 10,2024, the Fundamentals of ORCHID PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of ORCHID PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ORCHID PHARMA UnderValued or OverValued?
As on Sep 10,2024, ORCHID PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ORCHID PHARMA ?
As on Sep 10,2024, the Intrinsic Value of ORCHID PHARMA is Rs. 729.22 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 936.30
Fair Value [Median EV / Sales Model] : Rs. 729.22
Fair Value [Median Price / Sales Model] : Rs. 233.92
Estimated Median Fair Value of ORCHID PHARMA : Rs. 729.22
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.